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Vitamin D for Covid-19? 
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A small survey of literature about Vitamin D  and inhibition and expression of interleukins and
tumor necrosis factors. Could Vitamin D have a possible role in Covid-19 Cytokine Release
Syndrome?  A study of its role when tocilizumab is used exists, and therefore Vitamin D could be
considered when tocilizumab is involved in the mitigation of the cytokine storm. However, another
question also exists and it is the following. Might Vitamin D induce antimicrobial peptides to
reduce SARS-CoV-2 replication?
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In [1], we have considered some literature about Covid-19 Cytokine Release Syndrome, known as
"cytokine storm". Cytokines are proteins which are released by many different cells in the body,
including those of the immune system. Then, these proteins have a role in coordinating the body’s
response against infection and trigger inflammation. When it happens that excessive or uncontrolled
levels  of cytokines  are  released,  with a  consequent  activation  of  more immune cells,  the body
suffers  a  hyper-inflammation,  that  is,  a  "cytokine  storm".  The  cytokine  storms  are  a  common
complication of Covid-19, influenza, SARS and MERS. "The term was popularized largely in the
context of avian H5N1 influenza virus infection, bringing the term into popular media" [2]. 
In [1] we mentioned two articles, [3] and [4], where Vitamin D is considered.
Let us start from [4], where M. Silberstein asks: "Vitamin D: A simpler alternative to tocilizumab
for trial in COVID-19?".  Then, a possible question is: could Vitamin D have a possible role in
Covid-19 Cytokine Release Syndrome? The question is posed in this form, because tocilizumab is a
drug used against Covid-19 Cytokine Release Syndrome. 
"Tocilizumab, also known as atlizumab, is an immunosuppressive drug, mainly for the treatment of
rheumatoid arthritis ... . It is a humanized monoclonal antibody against the interleukin-6 receptor
(IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is
implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma
and prostate cancer". https://en.wikipedia.org/wiki/Tocilizumab 
Then, let us search for literature, at the beginning, about Vitamin D and interleukins.
Actually,  in  [5],  we  find  Vitamin  D  involved  with  tocilizumab.  The  article  is  entitled  "1,25-
dihydroxy Vitamin D3 and Interleukin-6 Blockade Synergistically Regulate Rheumatoid Arthritis by
Suppressing  Interleukin-17  Production  and  Osteoclastogenesis".  It  is  told  that  "Immune  cells
express  the  vitamin  (vit)  D  receptor,  and  vit  D  is  a  potent  immune-modulator.  A  negative
correlation between serum vit  D levels  and rheumatoid  arthritis  (RA) disease activity  has been
reported. Therefore," the authors of [5] "aimed to investigate if the sufficient serum vit D level is
helpful to control disease activity in RA patients treated with interleukin (IL)-6 receptor antibody
tocilizumab".   RA  patients  taking  tocilizumab  were  enrolled,  and  data  were  collected
retrospectively. "RA patients treated with IL-6 antibody show a better response when they have
sufficient serum vit D. Tocilizumab and 1,25(OH)₂D synergistically suppress IL-17 production and
osteoclast differentiation in RA patients".
In  [6],  "Vitamin  D as  a  Principal  Factor  in  Mediating  Rheumatoid  Arthritis-Derived  Immune
Response" is discussed in a mini-review. The abstract tells "Rheumatoid arthritis (RA) is a systemic
multifactorial  autoimmune  disorder.  ...  Serum  levels  of  vitamin  D  (VD)  are  involved  in  the
regulation of various immune responses. Vitamin D is a key signaling molecule in the human body
that  maintains  calcium as  well  as phosphate homeostasis.  It  also regulates  the functions  of the
immune  system  and,  thus,  can  play  a  substantial  role  in  the  etiology  of  various  autoimmune
disorders, including RA. Low serum VD levels have been found to be associated with a higher risk
of RA, although this finding has not been replicated consistently. The molecular mechanisms by
which VD influences autoimmunity need to be further explored to understand how variation in
plasma VD levels could affect the pathogenesis of RA. This mini-review focuses on the influence of
VD  and  its  serum  levels  on  RA  susceptibility,  RA-associated  complexities,  treatment,  and
transcriptome products of key proinflammatory cytokines, along with other cytokines that are key
regulators of inflammation in rheumatoid joints".
In [6] it  is told that the cytokines involved in RA can be grouped into two main categories of
proinflammatory  and  anti-inflammatory  cytokines.  "Tumor  necrosis  factor  alpha  (TNFα),
interleukin1  (IL-1),  interleukin6  (IL-6),  and  interleukin17  (IL-17)  are  key  proinflammatory
cytokines. ... IL-6 also regulates the activation and differentiation of various immune cells. ...Since
the  focus  of  this  short  review  is  on  the  effect  of  VD  on  proinflammatory  cytokines,  anti-
inflammatory cytokines are not discussed" in [6].
The section 5 of this reference discusses Vitamin D and Tumor Necrosis Factor-Alpha (TNFα).
Among the papers mentioned we find [7]; it is a study "conducted on healthy women" that "showed
an inverse correlation between VD and TNFα concentration and suggested the preventive role of
VD against inflammatory conditions". Abstract of [7] tells that "Circulating 25 hydroxyvitamin D
(25 (OH)D),  an  accurate  measure  of  vitamin  D status,  is  markedly  greater  in  individuals  with
increased exposure to ultraviolet B (UVB) light via sunlight or the use of artificial UV light. Aside
from the known relationship between vitamin D and bone, vitamin D has also been implicated in
immune function and inflammation. Furthermore, a mass of evidence is accumulating that vitamin
D deficiency could lead to immune malfunction. Our overall objective was to study the relationship
between vitamin D status (as determined by serum 25(OH) D concentrations) and inflammatory
markers in healthy women".
Sections  6-9  of  Ref.[6]  are  discussing  Vitamin  D and  interleukins  and other  cytokines.  In  the
Section 7, it is considered Interleukin-6. "Serum levels of VD have been reported to be inversely
related to serum IL-6 levels" [8]. Ref.8 tells that "Vitamin D deficiency has been linked to various
inflammatory  diseases.  However,  the  mechanism  by  which  vitamin  D  reduces  inflammation
remains  poorly  understood".  In  [8],  the  researchers  "investigated  the  inhibitory  effects  of
physiologic levels of vitamin D on LPS-stimulated [lipopolysaccharide] inflammatory response in
human blood monocytes and explored potential mechanisms of vitamin D action". Two forms of the
vitamin  D,  1,25(OH)2D3,  and  25(OH)D3,  have  been  considered".  "In  conclusion,"  -  tell  the
authors, - their "study identified the upregulation of MKP-1 by vitamin D as a novel pathway by
which  vitamin  D  inhibits  LPS-induced  p38  activation  and  cytokine  production  in
monocytes/macrophages".
In [9], the reference is entitled "Inhibition of p38 by vitamin D reduces interleukin-6 production in
normal prostate cells via mitogen-activated protein kinase phosphatase 5: implications for prostate
cancer prevention by vitamin D". In the abstract: "Activation of p38 and downstream production of
interleukin  6  (IL-6)  are  proinflammatory.  Inflammation  and  IL-6  overexpression  have  been
implicated in the initiation and progression of prostate cancer. 1,25D pretreatment inhibited both
UV- and tumor necrosis factor alpha-stimulated IL-6 production in normal cells via p38 inhibition.
Consistent with inhibition of p38, 1,25D decreased UV-stimulated IL-6 mRNA stabilization. The
ability of 1,25D to up-regulate MKP5 was maintained in primary prostatic adenocarcinoma cells but
was  absent  in  metastases-derived  prostate  cancer  cell  lines.  The  inability  of  1,25D to  regulate
MKP5 in the metastasis-derived cancer cells suggests there may be selective pressure to eliminate
key tumor suppressor functions of vitamin D during cancer progression. These studies reveal MKP5
as a mediator  of p38 inactivation and decreased IL-6 expression by 1,25D in primary prostatic
cultures of normal and adenocarcinoma cells,  implicating decreased prostatic  inflammation as a
potential mechanism for prostate cancer prevention by 1,25D". 
1,25D is 1,25-dihydroxyvitamin-D3. "1,25-Dihydroxyvitamin D(3) (1,25D) is known primarily as a
regulator of calcium, but 1,25D also promotes phosphate absorption from intestine, reabsorption
from kidney, and bone mineral resorption" [10].
In  [11],  we  find  a  work  entitled  "Vitamin  D  Induces  Interleukin-1β  Expression:  Paracrine
Macrophage  Epithelial  Signaling  Controls  M.  tuberculosis  Infection".  "Although  vitamin  D
deficiency is a common feature among patients presenting with active tuberculosis, the full scope of
vitamin D action during Mycobacterium tuberculosis (Mtb) infection is poorly understood." The
authors used the hormonal form of vitamin D, 1,25-dihydroxyvitamin D (1,25D). The researchers
"focused on the role of 1,25D- and infection-induced interleukin 1β (IL-1β) expression in response
to infection. 1,25D enhanced IL-1β expression via a direct transcriptional mechanism. Secretion of
IL-1β  from infected  cells  required  the  NLRP3/caspase-1  inflammasome.  The  impact  of  IL-1β
production was investigated in a novel model ... [The] data provide evidence that the anti-microbial
actions of vitamin D extend beyond the macrophage by modulating paracrine signaling, reinforcing
its role in innate immune regulation in humans."
In  [12],  the  research  is  entitled  "Relationships  among  interleukin‐6,  tumor  necrosis  factor‐α,
adipokines, vitamin D, and chronic periodontitis". The aim of the researchers was that of exploring
"relationships  among  serum  adipokines,  vitamin  D,  and  clinical  and  microbial  parameters  of
chronic  periodontitis  before  and  after  treatment".  "Weight,  height,  and  smoking  status  were
recorded  for  56  patients  with  chronic  periodontitis.  Plaque,  gingivitis,  bleeding  on  probing,
suppuration,  probing  depth,  and  clinical  attachment  level  were  measured  at  all  teeth  present.
Subgingival biofilm samples from each tooth were analyzed for levels of 40 bacterial species using
checkerboard DNA-DNA hybridization. Serum levels of interleukin-6 (IL-6), tumor necrosis factor-
α, adiponectin, leptin, resistin, and vitamin D were measured at baseline. Sample collection was
then performed in a subset of the population 6 months after therapy (n = 17). Serum samples were
analyzed  ...".  About  the  results,  the  authors  write:  "There  were  positive  correlations  between
adiponectin/vitamin D and between IL-6/leptin, negative correlations between IL-6/vitamin D and
leptin/vitamin D, but no associations between serum analytes and clinical or microbial parameters.
Sex and body mass index were associated with levels of adipokines. Periodontal therapy improved
clinical  and microbiologic  parameters  but  did not  influence  the levels  of  serum analytes".  The
CONCLUSION is also interesting "Adipokines and IL-6 levels were affected by sex and body mass
index".
In [13], we find discussed: "Vitamin D derivatives: calcitriol and tacalcitol inhibits interleukin-6
and interleukin-8 expression in human nasal polyp fibroblast cultures". "Biologically active vitamin
D3 (VD) derivatives possess modulatory activities on immunological and inflammatory responses
which can be reflected by altered levels of pro-inflammatory chemokines. Nasal polyposis (NP),
defined as a chronic inflammatory process of upper respiratory system, could be influenced by VD
derivatives.  The  purpose  of  this  study  was  to  investigate  the  influence  of  1alpha,25-
dihydroxyvitamin  D3  (calcitriol)  and  1alpha,24(R)-dihydroxyvitamin  D3  (tacalcitol)  on  the
secretion of IL-6 and IL-8 by fibroblasts derived from NP. ... Treatment with calcitriol or tacalcitol
inhibits the synthesis of both IL-6 and IL-8 compared to the control group. The dose dependence of
this  effect  has  been confirmed.  VD derivatives  influence  was marked at  higher  concentrations.
Significant interleukin decrease was observed at 10(-5) and 10(-4) for calcitriol and 10-4 in the case
of tacalcitol". The authors in [13] tell that their study "demonstrates that calcitriol and tacalcitol are
capable of affecting pro-inflammatory cytokine (IL-6 and IL-8) levels in NP cultures.  Our data
imply  a  potential  therapeutical  application  of  topical  VD derivates  in  NP and  warrant  further
investigation".
"Calcitriol  is  the  active  form  of  vitamin  D,  normally  made  in  the  kidney".  https://
en.wikipedia.org/wiki/Calcitriol ; "Tacalcitol (1,24-dihydroxyvitamin D3) is a synthetic vitamin D3
analog.  Tacalcitol  is  marketed  under  several  names,  including  Curatoderm  and  Bonalfa".
https://en.wikipedia.org/wiki/Tacalcitol
By means of the previous works, we have searched for an answer to the question "Could Vitamin D
have a possible role in Covid-19 Cytokine Release Syndrome?". A study [5] of the role of this
vitamin  when  tocilizumab  is  used  exists,  and  therefore  Vitamin  D  could  be  considered  when
tocilizumab is involved in the mitigation of the cytokine storm. And now, let us consider the other
question "Might Vitamin D induce antimicrobial  peptides to reduce SARS-CoV-2 replication?".
The reason of it is in Ref.3, entitled "Current status of potential therapeutic candidates for the
COVID-19 crisis".
In [3], it is told that "Vitamin D might induce antimicrobial peptides to reduce SARS-CoV-2
replication". However, no references are given where this sentence is written. But a section in [3]
tells  that  "Vitamin  D  is  known  to  modulate  the  innate  and  adaptive  immune  system,  and  its
deficiency is associated with increased autoimmunity as well as in an increased susceptibility to
infection (Aranow, 2011) [14]. Grant et al. (2020) [15] pointed the role of vitamin D in reducing the
risk of respiratory tract infections by COVID-19. Actions of mechanism of vitamin D include the
induction  of  antimicrobial  peptides  (i.e.,  cathelicidins  and  defensins)  that  can  reduce  viral
replication rate and impeding pro-inflammatory cytokines. Several clinical trials of vitamin D in
patients with COVID-19 (i.e., NCT04334005, NCT04344041) are underway".
In [14], "Vitamin D and the Immune System", abstract tells that "It is now clear that vitamin D has
important roles in addition to its classic effects on calcium and bone homeostasis. As the vitamin D
receptor is expressed on immune cells (B cells, T cells, and antigen-presenting cells), and these
immunologic cells are all capable of synthesizing the active vitamin D metabolite, vitamin D has
the capability  of acting  in an autocrine manner in a local  immunologic milieu.  Vitamin D can
modulate the innate and adaptive immune responses. Deficiency in vitamin D is associated with
increased  autoimmunity  and  an  increased  susceptibility  to  infection.  As  immune  cells  in
autoimmune diseases are responsive to the ameliorative effects of vitamin D, the beneficial effects
of supplementing vitamin D-deficient individuals with autoimmune disease may extend beyond the
effects on bone and calcium homeostasis".
In  [15],  "Evidence  that  Vitamin  D  Supplementation  Could  Reduce  Risk"  of  respiratory  tract
infections is discussed, also concerning the "epidemiology of influenza and COVID-19, and how
vitamin D supplementation might be a useful measure to reduce risk. Through several mechanisms,
vitamin  D can reduce risk of  infections.  Those  mechanisms include  inducing cathelicidins  and
defensins that can lower viral  replication rates and reducing concentrations of pro-inflammatory
cytokines that produce the inflammation that injures the lining of the lungs, leading to pneumonia,
as well as increasing concentrations of anti-inflammatory cytokines". The authors in [15] tells that
"several observational studies and clinical trials reported that vitamin D supplementation reduced
the risk of influenza, whereas others did not".And also that "Evidence supporting the role of vitamin
D in reducing risk of COVID-19 includes that the outbreak occurred in winter, a time when 25-
hydroxyvitamin D (25(OH)D) concentrations are lowest; that the number of cases in the Southern
Hemisphere near the end of summer are low; ... ". Some recommendation of assume vitamin D3 are
given.  However "Randomized controlled trials and large population studies should be conducted to
evaluate these recommendations".
About NCT04334005 and NCT04344041 we have the following links.
"Vitamin D on Prevention and Treatment of COVID-19 (COVITD-19)"
"Vitamin D is a hormone precursor produced by our own body with the help of sunlight which has
an important role on adaptive immunity and cellular differentiation, maturation and proliferation of
several immune cells. Reduced levels of vitamin D in calves were positioned as the main cause of
bovine coronavirus infection in the past. Therefore, it seems plausible that the use of vitamin D as a
nutritional  ergogenic  aid  could  be  a  potential  intervention  to  fight  against  COVID-19 infected
patients which remain asymptomatic or which have non-severe and severe symptoms". The study
NCT04334005 "aims to investigate whether the use of vitamin D as an immune modulator agent
induces significant improvements of health status and outcomes in non-severe symptomatic patients
infected with COVID-19 as well as preventing COVID-19 health deterioration". It is hypothesized
"that  vitamin  D  will  significantly  improve  hard  endpoints  related  to  COVID-19  deleterious
consequences  compared  with  a  usual  care  control  group".  https://clinicaltrials.gov/ct2/show/
NCT04334005
"COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High
Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial)"
"Preclinical research suggests that the SARS-Cov-2 virus enters cells via the angiotensin converting
enzyme 2 (ACE2). Coronavirus viral replication downregulates ACE2, thereby dysregulating the
renin-angiotensin  system  (RAS)  and  leading  to  a  cytokine  storm  in  the  host,  causing  acute
respiratory  distress  syndrome  (ARDS).  Research  also  shows  that  vitamin  D  plays  a  role  in
balancing RAS and in reducing lung damage. On the contrary, chronic hypovitaminosis D induces
pulmonary  fibrosis  through activation  of RAS. Similarly,  hypovitaminosis  D has  been strongly
associated in the literature with ARDS, as well as with a pejorative vital prognosis in resuscitation
but also in geriatric units, and with various comorbidities associated to deaths during SARS-Cov-2
infections. Conversely, vitamin D supplementation has been reported to increase immunity and to
reduce inflammatory responses and the risk of acute respiratory tract infections". It is also told that
"Vitamin D supplementation is mentioned as a potentially interesting treatment for SARS-Cov-2
infection but on a scientific basis with a low level of evidence until now". https://clinicaltrials.gov/
ct2/show/NCT04344041
In  [16],  we  find  a  preprint  entitled:  "Tripartite  combination  of  potential  pandemic  mitigation
agents: Vitamin D, Quercetin, and Estradiol manifest properties of candidate medicinal agents for
mitigation of the severity of pandemic COVID-19 defined by genomics-guided tracing of SARS-
CoV-2 targets in human cells." In the abstract, we find that "Genes required for SARS-CoV-2 entry
into  human  cells,  ACE2  and  FURIN,"  can  be  "employed  as  baits  to  build  genomics-guided
molecular maps of up-stream regulatory elements, their expression and functions in human body,
including  pathophysiologically-relevant  cell  types.  Repressors  and  activators  of  the  ACE2  and
FURIN  genes  were  identified  based  on  the  analyses  of  gene  silencing  and  overexpression
experiments as well as relevant transgenic mouse models". Panels of repressors and activators were
then employed "to identify existing drugs manifesting gene expression signatures of the potential
coronavirus infection mitigation agents. Using this strategy, Vitamin D and Quercetin have been
identified as putative COVID-19 mitigation agents". 
Now, let us consider other two works about Vitamin D.
In [17]: "The present aim was to propose an hypothesis that there is a potential association between
mean levels of vitamin D in various countries with cases and mortality caused by COVID-19. The
mean  levels  of  vitamin  D  for  20  European  countries  and  morbidity  and  mortality  caused  by
COVID-19 were acquired. ... Vitamin D levels are severely low in the aging population especially
in Spain, Italy and Switzerland. This is also the most vulnerable group of the population in relation
to  COVID-19.  It  should  be  advisable  to  perform dedicated  studies  about  vitamin  D  levels  in
COVID-19 patients with diferent degrees of disease severity".
In  https://www.news-medical.net/news/20200429/Low-levels-of-vitamin-D-may-be-linked-to-
severe-COVID-19.aspx we find an article entitled "Low levels of vitamin D may be linked to severe
COVID-19", by Tomislav Meštrović, Apr 29 2020. "A new observational study from the United
States  indicates  that  vitamin  D insufficiency  may play  a  significant  role  in  the  progression  of
coronavirus  disease  (COVID-19).  The  research  titled  'Vitamin  D  Insufficiency  is  Prevalent  in
Severe COVID-19' is available on the preprint server medRxiv".
Let us conclude with two links and two different expressions about Vitamin D. One of the link is
https://www.unitonews.it/index.php/it/news_detail/la-carenza-di-vitamina-d-un-fattore-di-rischio-
linfezione-da-coronavirus  26  mar  2020,  "La  carenza  di  vitamina  D:  un  fattore  di  rischio  per
l'infezione  da  Coronavirus?"  where  we  find  that  "I  Proff.  Giancarlo  Isaia  ed  Enzo  Medico
dell’Università  di  Torino  sul  possibile  ruolo  preventivo  e  terapeutico  della  vitamina  D  nella
gestione della pandemia da COVID-19".
The other link is related to [19], and it is https://www.cebm.net/covid-19/vitamin-d-a-rapid-review-
of-the-evidence-for-treatment-or-prevention-in-covid-19/
The authors tell that they found "no clinical evidence on vitamin D in COVID-19. There was no
evidence  related to vitamin D deficiency predisposing to COVID-19, nor were there studies of
supplementation for preventing or treating COVID-19. There is some evidence that daily vitamin
D3  supplementation  over  weeks  to  months  may  prevent  other  acute  respiratory  infections,
particularly  in  people  with  low  or  very  low  vitamin  D  status.  This  evidence  has  limitations,
including heterogeneity in study populations, interventions, and definitions of respiratory infections
that include upper and lower respiratory tract involvement."
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